Monday, May 22, 2017
MabVax Therapeutics Raises $4.1M In PIPE
San Diego-based MabVax Therapeutics has raised $4.1M in a Series G funding round, the company announced this morning, in a public offering of common stock and Series G Preferred stock. The company said that OPKO Health and its CEO and Chairman participated in the offering. MabVax is developing antibody-based products for treating cancer, and is publicly traded on the NASDAQ as MBVX.